NDA 202450 · Azurity
Tudorza Pressair
Aclidinium Bromide · Inhalation
NovelLast checked: Nov 20, 2026Latest source record: Mar 29, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2012
Jul 23, 2012
Approved uses
2
Original approval plus efficacy supplements
Registered trials
42
21 Phase 3, 0 recruiting
FAERS reports
6,392
3,559 serious, 290 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Aug 1, 2022.
TUDORZA® PRESSAIR® (aclidinium bromide inhalation powder) is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). TUDORZA PRESSAIR is an anticholinergic indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). (1)
Mechanism: Aclidinium bromide is a long-acting antimuscarinic agent, which is often referred to as an anticholinergic. It has similar affinity to the subtypes of muscarinic receptors M 1 to M 5 . In the airways, it exhibits pharmacological effects through inhibition of M 3 receptor at the smooth muscle leading to bronchodilation. The competitive and reversible nature of antagonism was shown with human and animal origin receptors and isolated organ preparations. In preclinical in vitro as well as in vivo studies, prevention of acetylcholine-induced bronchoconstriction effects was dose-dependent and...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Mar 29, 2019 Supplement 12 · Efficacy LabelLetter
- Jul 23, 2012 Original approval · Type 1 - New Molecular Entity NovelReviewLetterLabel
1 products under this application
- TUDORZA PRESSAIR · ACLIDINIUM BROMIDE 0.4MG/INH · POWDER, METERED, INHALATION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Aclidinium" as an intervention, any sponsor and status, largest first.
- Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and Exacerbations in Moderate to Very Severe COPD Patients.Pivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT01966107 · 3,635 participants · Start Oct 16, 2013 · Primary completion Sep 21, 2017
Drug: Aclidinium Bromide; Placebo · For: COPD; Chronic Obstructive Pulmonary Disease; Moderate to Very Severe COPD
Sites: Birmingham, Alabama; Florence, Alabama; Foley, Alabama · 468 sites in all
- Long-term Efficacy and Safety of Aclidinium Bromide/Formoterol Fumarate Fixed-Dose CombinationPivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT01462942 · 2,443 participants · Start Oct 2011 · Primary completion Jan 2013
Drug: Aclidinium Bromide/Formoterol Fumarate; Aclidinium Bromide/Formoterol Fumarate and 3 more · For: Chronic Obstructive Pulmonary Disease (COPD)
Sites: Graz, Austria; Salzburg, Austria; Edegem, Belgium · 197 sites in all
- Efficacy, Safety and Tolerability of Aclidinium Bromide/Formoterol Fumarate Compared With Aclidinium Bromide and Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)Pivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT01437397 · 1,692 participants · Start Sep 2011 · Primary completion Feb 2013
Drug: Aclidinium Bromide/Formoterol Fumarate; Aclidinium Bromide/Formoterol Fumarate and 3 more · For: Chronic Obstructive Pulmonary Disease
Sites: Anniston, Alabama; Athens, Alabama; Birmingham, Alabama · 222 sites in all
- Study to Assess Efficacy and Safety of Aclidinium Bromide and Aclidinium Bromide/Formoterol Fumarate in Stabile COPD PatientsPivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT03022097 · 1,625 participants · Start Feb 2, 2017 · Primary completion Apr 14, 2022
Drug: Aclidinium bromide/formoterol Fixed-Dose Combination; Aclidinium bromide and 2 more · For: COPD
Sites: Baotou, China; Beijing, China; Cangzhou, China · 74 sites in all
- AMPLIFY - D6571C00001 Duaklir USA Phase III StudyPivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT02796677 · 1,595 participants · Start Jul 5, 2016 · Primary completion Jun 8, 2017
Drug: Aclidinium bromide 400 μg/Formoterol Fumarate 12 μg (AB/FF 400/12 μg); Aclidinium bromide 400 μg (AB 400 μg) and 2 more · For: Chronic Obstructive Pulmonary Disease
Sites: Gulf Shores, Alabama; Phoenix, Arizona; Tucson, Arizona · 163 sites in all
- Evaluation of Tolerability and Pharmacokinetics of Roflumilast, 250μg and 500μg, as add-on to Standard COPD Treatment to Treat Severe COPDPivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT02165826 · 1,323 participants · Start May 1, 2014 · Primary completion Sep 1, 2015
Drug: Roflumilast; Roflumilast Placebo and 1 more · For: Chronic Obstructive Pulmonary Disease (COPD)
Sites: Bardejov, Slovakia; Spišská Nová Ves, Slovakia
- Study of Aclidinium Bromide/Formoterol Fumarate Compared With Salmeterol/Fluticasone Propionate in Patients With Chronic Obstructive Pulmonary Disease (COPD)Pivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT01908140 · 933 participants · Start Sep 2013 · Primary completion Aug 2014
Drug: Aclidinium Bromide / Formoterol Fumarate; Salmeterol / Fluticasone · For: Chronic Obstructive Pulmonary Disease (COPD)
Sites: Feldbach, Austria; Feldkirch, Austria; Grieskirchen, Austria · 126 sites in all
AstraZenecaAstraZeneca (AZN)
NCT01572792 · 921 participants · Start Apr 2012 · Primary completion Jun 2013
Drug: Aclidinium bromide/formoterol Fixed-Dose Combination (FDC); Aclidinium bromide/formoterol Fixed-Dose Combination (FDC) and 3 more · For: Chronic Obstructive Pulmonary Disease
Sites: Anniston, Alabama; Athens, Alabama; Birmingham, Alabama · 208 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- dyspnoea1,875
- device malfunction1,282
- drug dose omission1,017
- asthma819
- chronic obstructive pulmonary disease784
- intentional product misuse741
- off label use720
- pneumonia718
- wheezing666
- cough658
- product quality issue592
- device issue475
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2009 | 2 |
| 2010 | 5 |
| 2011 | 6 |
| 2012 | 12 |
| 2013 | 221 |
| 2014 | 339 |
| 2015 | 631 |
| 2016 | 862 |
| 2017 | 912 |
| 2018 | 875 |
| 2019 | 472 |
| 2020 | 385 |
| 2021 | 421 |
| 2022 | 402 |
| 2023 | 329 |
| 2024 | 262 |
| 2025 | 175 |
| 2026 | 81 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Tudorza Pressair (Aclidinium Bromide)
2024 spending
$5.1M
Beneficiaries
1,936
7,487 claims
Per beneficiary
$2,614
$383.18 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $25,612,948 |
| 2021 | $18,018,964 |
| 2022 | $14,437,296 |
| 2023 | $10,574,258 |
| 2024 | $5,059,840 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Deterioration of Nighttime Respiratory Mechanics in COPD: Impact of Bronchodilator Therapy.
Domnik NJ, James MD, Scheeren RE, et al. · Chest 2021 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Long-acting antimuscarinic therapy in patients with chronic obstructive pulmonary disease receiving beta-blockers.
Chapman KR, Wise RA, Scirica BM, et al. · Respir Res 2021 · Clinical Trial, Phase IV, Comparative Study
- Aclidinium bromide for stable chronic obstructive pulmonary disease.
Ni H, Soe Z, Moe S · Cochrane Database Syst Rev 2014 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Network meta-analysis of the efficacy and safety of monoclonal antibodies and traditional conventional dichotomous agents for chronic obstructive pulmonary disease.
Xiong Y, Hu JQ, Tang HL, et al. · Front Med (Lausanne) 2024 · Systematic Review
- Fixed-Dose Combinations of Long-Acting Bronchodilators for the Management of COPD: Global and Asian Perspectives.
Rhee CK, Yoshisue H, Lad R · Adv Ther 2019 · Research Support, Non-U.S. Gov't, Systematic Review
- Comparisons of exacerbations and mortality among LAMA/LABA combinations in stable chronic obstructive pulmonary disease: systematic review and Bayesian network meta-analysis.
Lee HW, Park J, Jang EJ, et al. · Respir Res 2020 · Comparative Study, Systematic Review
Sponsor: Azurity
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.